261 related articles for article (PubMed ID: 31058868)
1. Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer.
Ko H; Lee JH; Kim HS; Kim T; Han YT; Suh YG; Chun J; Kim YS; Ahn KS
Biomolecules; 2019 May; 9(5):. PubMed ID: 31058868
[TBL] [Abstract][Full Text] [Related]
2. Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines.
Kim HS; Kim T; Ko H; Lee J; Kim YS; Suh YG
Bioorg Med Chem; 2017 Oct; 25(19):5032-5040. PubMed ID: 28705432
[TBL] [Abstract][Full Text] [Related]
3. Eucannabinolide, a novel sesquiterpene lactone, suppresses the growth, metastasis and BCSCS-like traits of TNBC via inactivation of STAT3.
Zhu Z; Yuan J; Xu X; Wei Y; Yang B; Zhao H
Neoplasia; 2021 Jan; 23(1):36-48. PubMed ID: 33217668
[TBL] [Abstract][Full Text] [Related]
4. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
[TBL] [Abstract][Full Text] [Related]
5. Picrasidine G decreases viability of MDA-MB 468 EGFR-overexpressing triple-negative breast cancer cells through inhibition of EGFR/STAT3 signaling pathway.
Yamashita N; Kondo M; Zhao S; Li W; Koike K; Nemoto K; Kanno Y
Bioorg Med Chem Lett; 2017 Jun; 27(11):2608-2612. PubMed ID: 28427809
[TBL] [Abstract][Full Text] [Related]
6. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
[TBL] [Abstract][Full Text] [Related]
7. Arnicolide D Inhibits Triple Negative Breast Cancer Cell Proliferation by Suppression of Akt/mTOR and STAT3 Signaling Pathways.
Qu Z; Lin Y; Mok DK; Bian Q; Tai WC; Chen S
Int J Med Sci; 2020; 17(11):1482-1490. PubMed ID: 32669950
[TBL] [Abstract][Full Text] [Related]
8. Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells.
Chun J; Li RJ; Cheng MS; Kim YS
Cancer Lett; 2015 Feb; 357(1):393-403. PubMed ID: 25434800
[TBL] [Abstract][Full Text] [Related]
9. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
Liu CY; Su JC; Ni MH; Tseng LM; Chu PY; Wang DS; Tai WT; Kao YP; Hung MH; Shiau CW; Chen KF
Breast Cancer Res Treat; 2014 Jul; 146(1):71-84. PubMed ID: 24903225
[TBL] [Abstract][Full Text] [Related]
10. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
11. The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer.
Canesin G; Evans-Axelsson S; Hellsten R; Sterner O; Krzyzanowska A; Andersson T; Bjartell A
Eur Urol; 2016 Mar; 69(3):400-4. PubMed ID: 26144873
[TBL] [Abstract][Full Text] [Related]
12. Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer.
Chen Y; Ji M; Zhang S; Xue N; Xu H; Lin S; Chen X
J Drug Target; 2018 Dec; 26(10):920-930. PubMed ID: 29595328
[TBL] [Abstract][Full Text] [Related]
13. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
14. A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.
Zhang W; Yu W; Cai G; Zhu J; Zhang C; Li S; Guo J; Yin G; Chen C; Kong L
Cell Death Dis; 2018 Oct; 9(11):1098. PubMed ID: 30368518
[TBL] [Abstract][Full Text] [Related]
15. Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer.
Chen D; Ma Y; Li P; Liu M; Fang Y; Zhang J; Zhang B; Hui Y; Yin Y
Molecules; 2019 Jun; 24(12):. PubMed ID: 31242627
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
Liu CY; Su JC; Huang TT; Chu PY; Huang CT; Wang WL; Lee CH; Lau KY; Tsai WC; Yang HP; Shiau CW; Tseng LM; Chen KF
Mol Oncol; 2017 Mar; 11(3):266-279. PubMed ID: 28084011
[TBL] [Abstract][Full Text] [Related]
17. A Sesquiterpenoid from Farfarae Flos Induces Apoptosis of MDA-MB-231 Human Breast Cancer Cells through Inhibition of JAK-STAT3 Signaling.
Jang H; Ko H; Song K; Kim YS
Biomolecules; 2019 Jul; 9(7):. PubMed ID: 31337063
[TBL] [Abstract][Full Text] [Related]
18. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
[TBL] [Abstract][Full Text] [Related]
19. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer.
Dees S; Pontiggia L; Jasmin JF; Mercier I
Cancer Biol Ther; 2020 Jun; 21(6):506-521. PubMed ID: 32164483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
